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Enteral lactoferrin supplementation for very preterm 
infants: a randomised placebo-controlled trial
The ELFIN trial investigators group*
Summary
Background Infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. 
Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an 
antimicrobial protein processed from cow’s milk, prevents infections and associated complications. The aim of this 
large randomised controlled trial was to collect data to enhance the validity and applicability of the evidence from 
previous trials to inform practice.
Methods In this randomised placebo-controlled trial, we recruited very preterm infants born before 32 weeks’ 
gestation in 37 UK hospitals and younger than 72 h at randomisation. Exclusion criteria were presence of a severe 
congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Eligible 
infants were randomly assigned (1:1) to receive either enteral bovine lactoferrin (150 mg/kg per day; maximum 
300 mg/day; lactoferrin group) or sucrose (same dose; control group) once daily until 34 weeks’ postmenstrual age. 
Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus 
multifetal pregnancy. Parents, caregivers, and outcome assessors were unaware of group assignment. The primary 
outcome was microbiologically confirmed or clinically suspected late-onset infection (occurring >72 h after birth), 
which was assessed in all participants for whom primary outcome data was available by calculating the relative risk 
ratio with 95% CI between the two groups. The trial is registered with the International Standard Randomised 
Controlled Trial Number 88261002.
Findings We recruited 2203 participants between May 7, 2014, and Sept 28, 2017, of whom 1099 were assigned to the 
lactoferrin group and 1104 to the control group. Four infants had consent withdrawn or unconfirmed, leaving 
1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants 
(1093 [99·5%] of 1098 in the lactoferrin group and 1089 [99·0] of 1101 in the control group) were available for inclusion 
in the modified intention-to-treat analyses. 316 (29%) of 1093 infants in the intervention group acquired a late-onset 
infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0·95 
(95% CI 0·86–1·04; p=0·233). During the trial there were 16 serious adverse events for infants in the lactoferrin 
group and 10 for infants in the control group. Two events in the lactoferrin group (one case of blood in stool and one 
death after intestinal perforation) were assessed as being possibly related to the trial intervention.
Interpretation Enteral supplementation with bovine lactoferrin does not reduce the risk of late-onset infection in very 
preterm infants. These data do not support its routine use to prevent late-onset infection and associated morbidity or 
mortality in very preterm infants.
Funding UK National Institute for Health Research Health Technology Assessment programme (10/57/49).
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Late-onset infection (occurring >72 h after birth) is the 
most common serious complication associated with 
hospital care for preterm infants. The James Lind 
Alliance Preterm Birth Priority Setting Partnership has 
identified the development and assessment of improved 
methods to prevent infection in preterm infants as a 
research priority.1
The prevalence of late-onset infection is estimated to be 
higher than 20% in very preterm infants (ie, born before 
32 weeks’ gestation) reflecting their duration of exposure 
to invasive procedures and intensive care.2 Very preterm 
infants who acquire a late-onset infection have an 
increased risk of mortality and acute morbidities, 
including necrotising enterocolitis, retinopathy of pre-
maturity, and bronchopulmonary dysplasia.3 Late-onset 
infection is associated with adverse neuro developmental 
outcomes including visual, hearing, and cognitive im-
pairment, and cerebral palsy.4 Very preterm infants with 
late-onset infection spend a longer time in hospital than 
similar infants without infection.5 Late-onset infection has 
major consequences for health-care service management, 
delivery, and costs.
Lactoferrin, a member of the transferrin family of iron-
binding glycoproteins, is a key component of the 
mammalian innate response to infection. It is the major 
Lancet 2019; 393: 423–33
Published Online 
January 8, 2019 
http://dx.doi.org/10.1016/
S0140-6736(18)32221-9
See Comment page 382
*Members listed at the end of 
the report and in the appendix
Correspondence to: 
Prof William McGuire, Centre for 
Reviews and Dissemination, 
University of York, 
York YO10 5DD, UK 
william.mcguire@york.ac.uk
See Online for appendix
Articles
424 www.thelancet.com   Vol 393   February 2, 2019
whey protein in human breast milk, present at a 
concentration of about 1 mg/mL. Lactoferrin has broad 
microbiocidal activity by mechanisms such as cell-
membrane disruption, iron sequestration, inhibition of 
microbial adhesion to host cells, and prevention of 
biofilm formation.6 Lactoferrin also promotes the growth 
of probiotic bacteria, stimulates differentiation and 
proliferation of enterocytes and expression of intestinal 
digestive enzymes, and has direct intestinal immuno- 
modulatory and anti-inflammatory actions including 
suppression of free-radical activity.7,8
Very preterm infants typically ingest little or no milk 
during the early neonatal period and have low intake of 
lactoferrin.9 The low lactoferrin intake in the early neo-
natal period is exacerbated by any delays in establishing 
enteral feeding. Enteral supplementation with bovine 
lactoferrin has been proposed as a simple strategy to 
compensate for this immunodeficiency.10 Bovine lacto-
ferrin is about 70% homologous with human lactoferrin 
but has higher antimicrobial activity.11 It is inexpensive 
compared with human or recombinant lactoferrin, is 
available com mercially as a food supplement in a stable 
powder form, and is “generally recognised as safe” by the 
US Food and Drug Administration.12 The no-observed-
adverse-effect level is more than 2 g/kg per day in rats.13 
The European Food Safety Authority Panel concludes that 
bovine lactoferrin is safe for infants at the standard 
supplementation concentration (up to 210 mg/kg of 
bodyweight per day).14
The 2017 Cochrane review15 of enteral lactoferrin 
supplementation for preterm infants includes six ran-
domised controlled trials (RCTs) involving 1071 par tici -
pants in total. Meta-analyses suggest that lactoferrin 
supplementation reduces the risk of late-onset infection by 
about 40%. The risk of necrotising enterocolitis was found 
to decrease by about 60%. No adverse effects or intolerance 
were reported. Since the included trials were small 
and contained methodological weaknesses associated 
with selection and performance bias, and since meta-
analyses were limited by data availability and heterogeneity, 
the assessment of the Grading of Recommendations 
Assessment, Development and Evaluation working group 
of the quality of this evidence was low. The authors of the 
Cochrane review15 concluded that data from large, good-
quality RCTs of lactoferrin supplementation in very 
preterm infants were needed to enhance the validity and 
applicability of the evidence to inform practice.
The aim of the Enteral Lactoferrin in Neonates (ELFIN) 
trial was to provide those data.16
Methods
Study design
This randomised, parallel-group, placebo-controlled trial 
was done in neonatal units in the UK (37 recruiting 
sites and 97 continuing care sites; appendix). The 
trial protocol was approved by the National Research 
Ethics Service Committee East Midlands—Nottingham 2 
(Ref: 13/EM/0118). The protocol is available at the trial 
website and is published in summary.17 Protocol changes 
are listed in the appendix. Local approval and site-
specific assessments were obtained from National 
Health Service Trusts for trial sites.
Participants
Eligible participants were very preterm infants who were 
younger than 72 h at randomisation. Exclusion criteria 
were presence of a severe congenital anomaly, anticipated 
enteral fasting for longer than 14 days, or no realistic 
For the ELFIN trial website see 
https://www.npeu.ox.ac.uk/elfin
Research in context
Evidence before this study
The 2011 version of the Cochrane review of enteral lactoferrin 
supplementation in very preterm infants included one 
randomised controlled trial (RCT) done in 11 Italian neonatal 
centres. This trial, in which 331 infants participated, suggested 
that enteral supplementation with bovine lactoferrin reduced 
the incidence of late-onset infection by two thirds compared 
with controls. No evidence of an effect on mortality was found 
and no adverse effects or intolerance were reported. Because the 
effect size estimate might have been inflated by performance 
and detection bias and by other methodological weaknesses, 
the Cochrane review concluded that this evidence was 
insufficient to support a change in practice.
Added value of this study
The ELFIN trial shows that enteral supplementation of bovine 
lactoferrin (150 mg/kg per day until 34 weeks postmenstrual 
age) does not reduce the risk of late-onset infection, other 
morbidity, or mortality in very preterm infants. This is the 
largest trial of this intervention and the validity is enhanced by 
the methodological quality and power. The findings are broadly 
applicable to very preterm infants cared for in facilities in well 
resourced health services. There was no indication of any 
beneficial effects for infants with additional risk factors for 
late-onset infection, including extreme preterm birth
Implications of all the available evidence
The ELFIN trial findings contradict the existing evidence base 
and illustrate why high-quality evidence from adequately 
powered RCTs is needed to inform policy and practice. The 2017 
update of the Cochrane review includes six RCTs, but most were 
small and some contained other design and methodological 
weaknesses that might have introduced biases resulting in 
overestimation of the effect sizes. With more than twice as 
many participants than had been enrolled in all of the previous 
trials combined, the ELFIN trial generated more precise 
estimates of effect, and provides valid and applicable evidence 
that enteral bovine lactoferrin supplementation does not 
reduce the risk of late-onset infection or other morbidity or 
mortality in very preterm infants.
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prospect of survival. Written consent was sought from 
the parents after they had received a full verbal and 
written explanation of the trial. Parents who did not 
speak English were approached only if an adult 
interpreter was available. Trial participants or their 
parents were not offered any material incentive or 
compensation to take part. Parents remained free to 
withdraw their infant from the trial at any time without 
providing a reason or explanation. Parents were aware 
that this decision would have no impact on any aspects of 
their infant’s care.
Randomisation
To confirm participant eligibility, investigators supplied 
gestational age, sex, and time of birth. To proceed to 
randomisation, investigators confirmed that signed 
informed consent was available. Infants were randomly 
assigned (1:1) to receive either bovine lactoferrin 
(lactoferrin group) or sucrose (control group) using a 
minimisation algorithm to ensure balance between the 
groups in recruiting site (neonatal unit), sex, single 
versus multiple births, and gestational age in completed 
weeks. Twins or higher-order multiple birth infants were 
randomly allocated individually. Infants were considered 
to have been enrolled once they had been given a 
unique study number and allocated a treatment pack 
identification number. Allocation of participants was 
done via a secure web-based randomisation facility at 
the National Perinatal Epidemiology Unit (NPEU), 
University of Oxford. Telephone assistance and ran- 
domisation back-up was available at all times. Parents, 
clinicians, investigators, and outcome assessors were 
masked to group assignment. Clinicians could unmask a 
participant’s allocation via the randomisation website 
using a single-use access code provided in a sealed 
envelope. The reason for unmasking had to be recorded. 
Unmasking was only permitted if it was an emergency 
situation in which knowledge of treatment allocation was 
needed to guide the clinical management of the 
participant.
Dry bovine lactoferrin has a pale pink-brown tinge 
whereas sucrose was very light brown. The opaque 
containers used to store the products did not allow 
them to be seen unless the sealed stopper was removed 
intentionally. The lactoferrin powder had similar granu-
larity to sucrose so that when—before the addition of 
water and milk (see further details in the procedures 
section)—either product was shaken within the opaque, 
sealed pots it was not possible to distinguish lactoferrin 
from sucrose by the sound generated. Mixing the 
lactoferrin with sterile water and milk (either breastmilk 
or formula) generated foam that settled within 30 min 
after shaking. When the mixed lactoferrin was removed 
in a syringe with a purple plunger, the pink tinge to the 
lactoferrin was disguised by the colour of the milk which 
often resulted in a light brown colour, which varied 
markedly between batches of milk. As lactoferrin was 
more likely than sucrose to retain a light pink tinge, we 
supplied all sites with a laminated picture of a range of 
possible colours for the lactoferrin mixture in syringes, 
and stressed that this applied to both lactoferrin and 
sucrose.
Procedures
Trial participants were allocated to receive either bovine 
lactoferrin (Tatua Co-operative Dairy Company Ltd, 
Morrinsville, New Zealand) or sucrose (British Sugar, 
Peterborough, UK).
The investigational medicinal product (IMP) was 
processed at the UK Medicines and Healthcare Regulatory 
Authority (MHRA)—approved National Health Service 
clinical-trials pharmacy unit at the Royal Victoria Hospital, 
Newcastle-upon-Tyne, UK (MHRA Manufacturer’s 
Authorisations for IMP 17136). The lactoferrin manu-
facturer’s certificate of analysis confirmed absence of 
contamination from bovine transmissible spongiform 
encephalopathies, as per European Medicines Evaluation 
Agency standards. The pharmacy independently con- 
firmed IMP purity and uniformity, sterility, low humidity, 
temperature stability, and processing as per good 
manufacturing practice standards before the batch was 
released by the designated qualified person.
The IMP was packaged in individual doses (375 mg) in 
25 mL sealed, opaque pharmacy pots and assembled 
into participant packs. Boxes containing 24 identically 
numbered pots were labelled with the same pack 
identification number to indicate that they belonged to 
the same treatment course. At randomisation, the study 
number was added to the label of the allocated pack with 
the infant’s name and date of birth for checking before 
each administration of the IMP.
The IMP was prescribed at a dose of 150 mg/kg 
bodyweight per day (up to a maximum of 300 mg/day) 
and prepared for administration by addition by syringe of 
sterile water (4 mL) plus expressed breast milk or formula 
(1 mL). The pot was shaken vigorously by hand for 30 s to 
generate a mixture containing 75mg/mL of IMP. The 
mixture was allowed to stand for 30 min before removal 
for administration using an enteral feeding syringe.
The IMP was administered once daily via gastric tube 
once the infant’s enteral feed volume was more than 
12 mL/kg per day and continued until 34 weeks’ 
postmenstrual age. Infants could have had the dose 
split at the discretion of the responsible clinical team. 
All other aspects of care, including the timing of the 
commencement of enteral feeds and the type of milk 
feed used were as per local policy, practice, and 
discretion. Administration of the trial IMP might have 
been stopped temporarily. Missed doses did not 
necessitate the removal of an infant from the trial. Data 
continued to be collected as per protocol if the trial 
medication was stopped. As participants were inpatients 
in a neonatal unit they were monitored continuously, 
and samples were only collected when indicated 
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For the British Association of 
Perinatal Medicine categories 
of care see https://www.bapm.
org/resources/categories-
care-2011
clinically. When an infant completed the course of 
treatment, any unused IMP pots were accounted for and 
destroyed.
Outcomes
The primary outcome was microbiologically confirmed 
(panel 1) or clinically suspected (panel 2) late-onset 
infection, from trial entry until hospital discharge. 
Primary outcome was first assessed locally and then 
centrally by a blinded end-point review committee.
Secondary outcomes were microbiologically confirmed 
infection; all-cause mortality before hospital discharge; 
necrotising enterocolitis (Bell’s stage 2 or 3);19 severe 
retinopathy of prematurity treated medically or sur-
gically;20 bronchopulmonary dysplasia for which the 
infant is still receiving mechanical ventilator support 
or supplemental oxygen at 36 weeks’ post- menstrual 
age;21 a composite of invasive infection, major morbidity 
(necrotising enterocolitis, retinopathy of prematurity, 
or bronchopulmonary dysplasia), and mortality; total 
number of days of administration of antimicrobials per 
infant from trial entry until 34 weeks’ postmenstrual age; 
total length of stay until discharge home;and length of 
stay in intensive care, high dependency care, and special 
care, as defined by the British Association of Perinatal 
Medicine.
An end-point review committee masked to participant 
allocation reviewed all case report forms reporting 
episodes of late-onset infection or necrotising enterocolitis. 
Two members independently assessed adherence to case-
definitions and resolved any discrepancies by discussion 
or referral to a third committee member. Persisting 
uncertainties were discussed with the site principal 
investigator or research nurse or both.
Some adverse events were expected (necrotising 
enterocolitis, bronchopulmonary dysplasia, retinopathy 
of prematurity, death) because of the nature of the 
participant population and their routine care and 
treatment. No adverse drug reactions were expected from 
bovine lactoferrin. Expected serious adverse events were 
recorded on the case report forms. All other serious 
adverse events were reported by trial sites to the NPEU 
Clinical Trials Unit (CTU) within 24 h of being recognised. 
A standard operating procedure outlining the reporting 
procedure for clinicians was provided with the serious 
adverse events form and in the trial handbook. The NPEU 
CTU processed and reported the event as specified in its 
own standard operating procedures. All serious adverse 
events were reviewed by the independent Data Monitoring 
Committee (DMC) at regular intervals throughout the 
trial. The chief investigator notified all investigators of 
information that could affect the safety of participants.
Suspected unexpected serious adverse reactions 
(SUSAR) were reported to the MHRA and the approving 
Research Ethics Committee within 7 days, if life threat-
ening, and within 15 days for other SUSARs. A copy of the 
SUSAR form was forwarded to the Chair of the DMC. The 
Chair was provided with details of all previous SUSARs 
with their unmasked allocation. The chief investigator 
informed all investigators of any issues raised in a SUSAR 
that could affect the safety of participants.
The chief investigator submitted annually or on request 
a development safety update report to the competent 
authority, the approving research ethics committee, and 
the sponsor.
Post-hoc analyses assessed differential effects depen-
ding on the infecting microorganism identified for the 
microbiologically confirmed late-onset infection out-
come, and differential effects for the primary outcome 
depending on whether infants had or had not received 
probiotics as part of their routine care.
Statistical analysis
The sample size estimate was informed by a range of 
plausible primary outcome control event rates (CER) 
Panel 1: Definition of microbiologically confirmed late-onset infection*
Microbiological culture of potentially pathogenic bacteria (including coagulase-negative 
staphylococci species, but excluding probable skin contaminants such as diphtheroids, 
micrococci, propionibacteria, or a mixed flora) or fungi from blood or cerebrospinal fluid 
sampled aseptically more than 72 h after birth, and treatment, or clinician intention to 
treat, for 5 days or more with intravenous antibiotics (excluding antimicrobial 
prophylaxis) after investigation was done. If the infant died or was discharged or 
transferred before the completion of 5 days of antibiotics, this condition would still be 
met if the intention was to treat for at least 5 days.
*Adapted from the UK Neonatal Infection Surveillance Network case-definition.2
Panel 2: Definition of clinically suspected late-onset infection*
Absence of positive microbiological culture, or culture of a mixed microbial flora or of 
probable skin contaminants (ie, diphtheroids, micrococci, propionibacteria) only, and 
treatment or clinician intention to treat for 5 days or more with intravenous antibiotics 
(excluding antimicrobial prophylaxis) after the investigation was undertaken for an infant 
who presents at least 3 of the following clinical or laboratory features of invasive infection:
• increase in oxygen requirement or ventilatory support
• increase in frequency of episodes of bradycardia or apnoea
• temperature instability
• ileus or enteral feeds intolerance or abdominal distention
• reduced urine output to less than 1 mL/kg per h
• impaired peripheral perfusion (capillary refill time longer than 3 seconds, skin 
mottling or core-peripheral temperature gap greater than 2°C)
• hypotension (clinician-defined as needing volume or inotrope support)
• irritability, lethargy, or hypotonia (clinician-defined)
• increase in serum C-reactive protein concentrations to more than 15 mg/L or in 
procalcitonin concentrations to 2 ng/mL or more
• white blood cells count smaller than 4 × 10⁹/L or greater than 20 × 10⁹/L
• platelet count less than 100 × 10⁹/L
• glucose intolerance (blood glucose smaller than 40 mg/dL or greater than 180 mg/dL)
• metabolic acidosis (base excess less than –10 mmol/L or lactate concentration greater 
than 2 mmol/L)
*Adapted from the European Medicines Agency consensus criteria and predictive model.¹,⁸
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from 18% to 24%.2,3 In summary, with 90% power and 
two-sided 5% significance, to detect an absolute risk 
reduction of 5–5·8% (relative risk reduction of 24–28%) 
would require a total of up to 2200 participants if the 
CER was 18%, 2070 if the CER was 21%, and 2076 if the 
CER was 24%. This target sample size of 2200 allowed 
for an anticipated loss to follow-up of up to 5%.
Characteristics at randomisation were summarised 
with counts (percentages) for categorical variables, 
mean (SD) for normally distributed continuous variables, 
or median (IQR) for other continuous variables.
Primary and secondary outcomes for participants were 
analysed in the groups to which they were assigned 
excluding those who withdrew consent for their data to 
be used or for whom consent was not obtained. Safety 
data were collected for all participants randomly assigned 
to groups. Comparative analyses calculated the relative 
risk ratio (RR) with 95% CI for the primary outcome 
(99% CIs for all other dichotomous outcomes), the mean 
difference (99% CI) for normally distributed continuous 
outcomes, or the median difference (99% CI) for skewed 
continuous variables.
The groups were compared using regression analysis 
adjusting for the minimisation factors (ie, collaborating 
hospital, sex, gestational age at birth, and single or 
multiple birth) to account for the correlation between 
treatment groups introduced by balancing the random-
isation. For all binary outcomes, we used mixed effect 
Poisson models with robust standard errors. Centre was 
fitted as a random effect and mother’s identification 
nested within this to take account of clustering within 
centre and within multiples. The other minimisation 
factors were fitted as a fixed effect with sex and multiplicity 
of birth included as binary variables and gestational age 
modelled as a continuous variable. For all length-of-stay 
outcomes and the number of days of administration of 
antimicrobials, we used quantile regression with sex and 
multiplicity of birth included as binary variables and 
gestational age modelled as a continuous variable. The 
crude un adjusted and adjusted estimates were calculated 
with the primary inference to be based on the adjusted 
analysis.
The consistency of the effect of lactoferrin sup- 
p lementation on the primary outcome across specific 
subgroups of infants was assessed using the statistical 
test of interaction. Prespecified subgroups were number 
of completed weeks’ gestation at birth, and type of milk 
given to the participating infants during the trial period 
(human breast milk versus formula versus both human 
milk and formula).
The trial statisticians produced reports for the DMC 
and Trial Steering Committee (TSC). Data quality issues 
were reported to data management staff and investigated 
when appropriate or included in routine data validation 
checks, or both. The TSC and DMC meetings provided 
opportunities for external, independent review of 
summary data, with additional feedback on potential 
data quality issues being incorporated into ongoing data 
quality checks.
The analyses were done using Stata/SE version 13.1 for 
Windows.22
This trial is registered with the International Standard 
Randomised Controlled Trial, number 88261002.
Role of the funding source
The funder provided advice and support and monitored 
study progress but did not have a role in study design or 
data collection, analysis, and interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
2203 participants in 37 neonatal units were recruited 
between May 7, 2014, and Sept 28, 2017 (figure 1). 
1099 infants were randomly assigned to the  lactoferrin 
group and 1104 infants to the placebo group. Consent was 
not confirmed for one infant in the lactoferrin group and 
withdrawn for three infants in the placebo group; these 
infants were not included in the analysis of outcomes 
at discharge. Therefore, in total, 1098 infants in the 
lactoferrin group and 1101 in the placebo group were 
included in the modified intention-to-treat analyses. Data 
were not available for five infants in the lactoferrin group 
and 12 infants in the control group; hence, 1093 infants in 
the lactoferrin group and 1089 in the placebo group were 
included in the primary and secondary outcome analyses. 
Baseline characteristics and other demographic features 
of participating infants in the two treatment allocation 
groups are presented in table 1.
35 (2%) infants discontinued the intervention early, 
20 (2%) of 1098 in the lactoferrin group and 15 (1%) of 
1101 in the sucrose group (appendix). Parental consent 
remained for data collection for intention-to-treat 
analyses for 32 (91%) of the 35 infants.
Adherence was high for infants who continued to 
receive the IMP. The median percentage of days when an 
IMP dose was not given or not recorded was 4% (IQR 0 
to 18·18 for the lactoferrin group; IQR 0 to 16·22 for the 
control group) in both treatment groups. The median 
difference between expected dose and actual dose per day 
was 7 mg/kg per day (IQR: –9 to 0 for the lactoferrin 
group; IQR –27 to 0 for the control group) in both groups, 
and was 1 mg/kg per day (IQR –11 to 0; lactoferrin group) 
or 2 mg/kg per day (IQR –11 to 0; control group) if the 
days in which enteral feeds were stopped or withheld for 
more than 4 h were excluded.
The estimates of effect for the primary and secondary 
outcomes are presented in table 2.
Data were available for 2182 infants (99·0%; case 
report forms for primary or secondary outcomes were 
incomplete or non-verifiable for missing infants). 
316 (28·9%) of 1093 infants in the lactoferrin group 
acquired a micro biologically confirmed or clinically 
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suspected late-onset infection versus 334 (30·7%) of 
1089 in the control group (table 2). The adjusted RR 
was 0·95 (95% CI 0·86–1·04). Subgroup analyses did 
not show any significant inter actions for completed 
weeks’ gestation at birth or type of enteral milk received 
(figure 2).
Post-hoc analyses did not show any effects depending 
on the infecting microorganism identified for the micro- 
biologically confirmed late-onset infection out- come, nor 
did they appear to show any difference in primary outcome 
by trial group depending on whether infants had received 
probiotics as part of routine care or not (table 3).
There were no significant differences in secondary 
outcomes (table 2): microbiologically confirmed infection 
(RR 1·05 [99% CI 0·87–1·26]); all-cause mortality (1·05 
[0·66–1·68]); necrotising enterocolitis (1·13 [0·68–1·89]); 
retinopathy of prematurity (0·89 [0·62–1·28]); bron- 
chopulmonary dysplasia (RR 1·01 [0·90–1·13]); or a 
composite of infection, major morbidity, and mortality 
(1·01 [0·94–1·08]). There were no differences in the 
number of days of administration of antimicrobials until 
34 weeks’ postmenstrual age, length of stay in hospital, or 
length of stay in intensive care, high dependency care, or 
special care levels.
There were 16 serious adverse events (1·5%) reported 
for infants in the lactoferrin group (six [0·5%] severe; 
n=1093), and ten (0·9%) for the sucrose group 
(three [0·3%] severe; n=1089; table 4). Two serious 
adverse events—ie, one case of blood in stool (expected) 
and one death after intestinal perforation probably 
Lactoferrin 
group (n=1098)
Control group 
(n=1101)
Number of centres* 37 37
Male sex* 575/1098 (52%) 578/1099 (53%)
Infant age at randomisation 
in days, median (IQR)
2 (2–3) 2 (2–3)
Birthweight (g), mean (SD) 1125·9 (356·2) 1143·3 (367·1)
<500 8/1098 (1%) 7/1101 (1%)
500–749 172/1098 (16%) 172/1101 (16%)
750–999 254/1098 (23%) 244/1101 (22%)
1000–1249 268/1098 (24%) 255/1101 (23%)
1250–1499 199/1098 (18%) 199/1101 (18%)
≥1500 197/1098 (18%) 224/1101 (20%)
Birthweight <10th centile for 
gestational age
175/1097 (16%) 177/1098 (16%)
Gestation at delivery (completed 
weeks),* median (IQR)
29 (27–30) 29 (27–30)
<23 1/1098 (<1%) 1/1101 (<1%)
23 + 0 to 23 + 6 33/1098 (3%) 31/1101 (3%)
24 + 0 to 24 + 6 73/1098 (7%) 76/1101 (7%)
25 + 0 to 25 + 6 73/1098 (7%) 73/1101 (7%)
26 + 0 to 27 + 6 227/1098 (21%) 221/1101 (20%)
28 + 0 to 29 + 6 315/1098 (29%) 319/1101 (29%)
30 + 0 to 31 + 6 376/1098 (34%) 380/1101 (35%)
Mother’s age at randomisation in 
years, mean (SD)
30·3 (6·1) 30·4 (6·0)
Multiple pregnancy* 350/1098 (32%) 346/1101 (31%)
Caesarean section delivery 635/1098 (58%) 616/1101 (56%)
Membranes ruptured before 
labour
422/1093 (39%) 428/1097 (39%)
Membranes ruptured >24 h 
before delivery
286/1092 (26%) 264/1096 (24%)
Mother received antenatal 
corticosteroids
998/1093 (91%) 997/1099 (91%)
Infant heart rate >100 bpm at 
5 min from birth 
995/1090 (91%) 1010/1093 (92%)
Infant temperature on admission 
(°C), mean (SD)
36·9 (0·7) 37 (0·7)
Infant worst base excess within 
first 24 h of birth, mean (SD)
–6·2 (3·9) –6·3 (3·8)
Infant ventilated via endotracheal 
tube at randomisation
338/1098 (31%) 357/1101 (32%)
Infant had absent or reverse end 
diastolic flow in the umbilical 
artery antenatally
134/1079 (12%) 130/1081 (12%)
Unless otherwise stated, data are n/N (%); when N is not equal to the total 
number of infants in the group it means that data are missing for some of the 
infants. BPM=beats per minute. *Minimisation factor. 
Table 1: Infant and maternal baseline characteristics
Figure 1: Trial profile
Number of infants assessed for eligibility and excluded before randomisation is not available. *Consent to use data 
remained for 20 infants and, when available, data were included in the analysis. †Consent to use data remained for 
12 infants and, when available, data were included in the analysis.
1104 assigned to sucrose 
(control group)
16 excluded†
15 withdrawn
1 randomised at >72 h
 
1057 received full treatment
3 consent withdrawn
1101 included in modified
intention-to-treat
analyses
 
12 excluded
(primary-outcome
data not available)
5 excluded 
(primary-outcome
data not available)
1089 included in final
primary outcome
analyses
2203 randomly assigned
1099 assigned to lactoferrin 
(lactoferrin group)
 
27 excluded*
20 withdrawn
7 randomised at >72 h
1051 received full treatment
1 consent not confirmed
1098 included in modified
intention-to-treat
analyses
1093 included in final
primary outcome
analyses
21 received no doses 31 received no doses
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associated with necrotising enterocolitis (SUSAR)—
both in the lactoferrin group, were assessed as being 
possibly related to the trial intervention. The remaining 
24 serious adverse events were considered to be 
unrelated to the trial intervention.
Discussion
Our data indicate that enteral lactoferrin supplementation 
(150 mg/kg per day until 34 weeks’ postmenstrual age) 
does not reduce the risk of late-onset infection, other 
morbidity, or mortality in very preterm infants. This 
contradicts previous trial findings. The 2017 Cochrane 
review15 includes six RCTs, and meta-analyses suggest 
substantial reductions in late-onset infection and 
necrotising enterocolitis associated with lactoferrin 
supplementation in very preterm infants. These trials, 
however, were small and some contained design and 
methodological weaknesses that might have introduced 
performance and detection biases resulting in over-
estimation of the treatment effects. Given these concerns, 
the Cochrane review graded the evidence for key 
outcomes as low quality and concluded that data from 
large, methodologically-rigorous RCTs were needed to 
generate evidence of sufficient validity to inform policy 
and practice.
The ELFIN trial provides such evidence. We used 
practices to limit bias, such as central web-based 
randomisation for allocation concealment; masking of 
parents, caregivers, and investigators to the group 
allocation; and complete follow-up and assessment of 
the trial cohort with intention-to-treat analyses based 
on a prespecified statistical-analysis plan. The trial 
achieved recruitment of 2203 participants as per 
protocol, which was based on an a priori sample-size 
estimation. Demographic and prognostic characteristics 
were well balanced at randomisation. Interim analyses 
by the trial’s independent DMC used criteria to 
minimise the chances of spurious findings due to data 
fluctuations before a sufficient sample size was 
achieved.23,24 Adherence to the intervention was high, 
the proportion of protocol violations was low, and 
outcome data were available for more than 99% of the 
cohort. Event prevalence for the outcomes was broadly 
similar to that anticipated.2,3 Consequently, the trial had 
sufficient power and validity to detect reliably modest 
Lactoferrin group 
(n=1098)
Control group 
(n=1101)
Unadjusted risk ratio or 
median difference 
(95% CI or 99% CI)*†
Adjusted risk ratio or 
median difference 
(95% CI or 99% CI)*†‡
p value§
Microbiologically confirmed or clinically suspected late-onset 
infection
316/1093 (29%) 334/1089 (31%) 0·94 (0·83 to 1·07) 0·95 (0·86 to 1·04) 0·233
Microbiologically confirmed late-onset infection 190/1093 (17%) 180/1089 (17%) 1·05 (0·82 to 1·34) 1·05 (0·87 to 1·26) 0·490
All-cause mortality 71/1076 (7%) 68/1076 (6%) 1·04 (0·69 to 1·59) 1·05 (0·66 to 1·68) 0·782
NEC (Bell stage II or III) 63/1085 (6%) 56/1084 (5%) 1·12 (0·71 to 1·77) 1·13 (0·68 to 1·89) 0·538
Severe ROP treated medically or surgically 64/1080 (6%) 72/1080 (7%) 0·89 (0·58 to 1·35) 0·89 (0·62 to 1·28) 0·420
BPD at 36 weeks’ postmenstrual age 358/1023 (35%) 355/1027 (35%) 1·01 (0·87 to 1·18) 1·01 (0·90 to 1·13) 0·867
Died before 36 weeks’ postmenstrual age 64 60 ·· ·· ··
Infection, NEC, ROP, BPD, or mortality 525/1092 (48%) 521/1094 (48%) 1·01 (0·90 to 1·13) 1·01 (0·94 to 1·08) 0·743
Total number of days of administration of antimicrobials 
from commencement of investigational medicinal product 
until 34 weeks’ postmenstrual age, median (IQR)
2 (0 to 8) 3 (0 to 8) 0 (0 to 0) 0 (–1 to 1) 0·625
Length of hospital stay (days) to discharge, median (IQR) 59 (40 to 85) 58 (40 to 84) 1 (–2 to 4) 1 (–1 to 3) 0·446
Days in level 1 (intensive) care, median (IQR) 8 (4 to 16) 8 (4 to 16) 0 (–1 to 1) 0 (–1 to 1) 0·963
Days in level 2 (high dependency) care, median (IQR) 10 (3 to 30) 9 (3 to 29) 0 (–1 to 1) 1 (–1 to 3) 0·420
Days in level 3 (special) care, median (IQR) 29 (21 to 39) 30 (22 to 39) –1 (–2 to 1) –1 (–3 to 1) 0·216
Unless otherwise stated, data are n/N (%); when N is not equal to the total number of infants in the group it means that data are missing for some of the infants. NEC=necrotising enterocolitis. 
BPD=bronchopulmonary dysplasia. ROP=retinopathy of prematurity. *Risk ratios for binary outcomes and median differences for continuous outcomes. †95% CI for microbiologically confirmed or clinically 
suspected late-onset invasive infection, 99% CI for all other outcomes. ‡Adjusted for minimisation factors (ie, collaborating hospital, sex, gestational age at birth, and single or multiple birth). §p value for testing 
whether adjusted risk ratio is equal to 1 or adjusted median difference is equal to 0.
Table 2: Primary and secondary outcomes
Figure 2: Subgroup analyses for confirmed or suspected late-onset invasive infection
p values are for statistical interactions. n=cases of late-inset invasive infection. N=group size. 
Formula only
Mixed
Breast only
Type of milk
≥30
28 + 0 to 29 + 6
26 + 0 to 27 + 6
25 + 0 to 25 + 6
24 + 0 to 24 + 6
<24 
Gestational age, weeks
10/53
199/707
99/315
24/375
69/311
107/227
45/73
46/73
25/34
Lactoferrin (n/N)
12/60
228/710
83/291
36/374
72/316
99/220
44/73
56/75
27/31
Placebo (n/N) Risk ratio (95% CI)
1·06 (0·58–1·91)
0·89 (0·79–1·01)
1·03 (0·88–1·21)
0·66 (0·42–1·03)
0·98 (0·74–1·29)
1·04 (0·85–1·28)
1·03 (0·73–1·45)
0·84 (0·69–1·03)
0·91 (0·69–1·20)
p value
0·400
0·273
Favours lactoferrin Favours placebo
0·25 0·5 1·0 2·0 4·0
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yet important effects on the risk of late-onset infection 
and other morbidity.
The ELFIN trial enrolled more than twice as many 
infants than had participated in all of the existing trials 
combined and generated more precise estimates of 
effect size than were previously available. Our relative 
risk estimate (0·95, 95% CI 0·86–1·04) for the primary 
outcome is consistent with a possible risk reduction of 
up to 14% and an increase in risk of up to 4%. These 
estimates were consistent across gestational age 
bands, making it unlikely that bovine lactoferrin has 
any important benefits for extremely preterm infants 
(ie, born before 28 weeks’ gestation) who have an 
increased risk of infection. Similarly, although plausible 
that lactoferrin might have had different effects in 
infants with low levels of exposure to the immuno- 
protective factors present in human milk, we did not 
show any interaction with the type of enteral milk feeds 
received during the trial period (human milk, formula, 
or both).
Lactoferrin group 
(n=1098)
Control group 
(n=1101)
Microbiologically confirmed late-onset invasive infection from 
trial entry until hospital discharge
190/1093 (17·4%) 180/1089 (16·5%)
At least one Gram-positive organism confirmed 153/1093 (14·0%) 147/1089 (13·5%)
At least one CoNS group organism 122/1093 (11·2%) 111/1089 (10·2%)
At least one Gram-negative organism confirmed 46/1093 (4·2%) 39/1089 (3·6%)
At least one fungal organism confirmed 3/1093 (0·3%) 2/1089 (0·2%)
At least one other organism confirmed 3/1093 (0·3%) 2/1089 (0·2%)
Any record of probiotics being given
Yes 99/354 (28·0%) 97/329 (29·5%)
No 208/728 (28·6%) 227/749 (30·3%)
Data for late-onset infection by classification of microorganism are n/N (%); when N is not equal to the total number 
of infants in the group it means that data are missing for some of the infants. Data for exposure to probiotics are 
number of infants with microbiologically confirmed or clinically suspected late-onset infection/number of infants who 
were given (or not) probiotics (%). CoNS=coagulase-negative staphylococcus.
Table 3: Microbiologically confirmed late-onset infection by classification of microorganism (appendix) 
and microbiologically confirmed or clinically suspected late-onset infection from trial entry until hospital 
discharge by exposure to probiotics
Age 
(days)
Brief description of event Severity Related to trial
Lactoferrin group (n=1098)
1 12 Meconium ileus following one dose of investigational medicinal product; resolved with laparotomy, 
no bowel removed
Moderate No
2 30 Two episodes of clinical seizures, resolved with brief course of anticonvulsant Moderate No
3 59 Cluster of seizures, probably related to severe Gram-negative bacteraemia and sepsis (ultimately fatal) Severe No
4 12 Episode of supraventricular tachycardia, resolved with adenosine and propranolol Mild No
5 49 Metabolic acidosis (likely renal tubular acidosis), resolved with sodium bicarbonate Severe No
6 20 Episode of supraventricular tachycardia, resolved with face cooling Mild No
7 19 Suspected necrotising enterocolitis Moderate No
8 18 Cluster of clinical seizures, resolved with magnesium sulphate and course of phenobarbitone Mild No
9 81 Infective exacerbation of chronic lung disease, resolved with antibiotics and corticosteroids Severe No
10 17 Large inferior vena cava thrombus Moderate No
11 68 Acute airway obstruction, resolved with respiratory support Severe No
12 44 Aspiration pneumonitis resolved with respiratory support Severe No
13 21 Blood in stool, unknown cause, resolved spontaneously Moderate Possibly (expected)
14 19 Haemolytic anaemia, unknown cause, resolved spontaneously Mild No
15 10 Death following intestinal perforation secondary to necrotising enterocolitis Severe Possibly (SUSAR)
16 27 Death attributed to Gram-negative bacteraemia Severe No
Control group (n=1101)
1 61 Rib fracture secondary to osteopenia of prematurity, resolved with supportive care and nutrient 
supplementation
Moderate No
2 50 Superior sagittal sinus non-occlusive thrombus, resolved with heparin (6 weeks of treatment) Moderate No
3 48 Hyperammonaemia, unknown cause, resolved with course of sodium benzoate Moderate No
4 36 Death attributed to infection and sepsis Severe No
5 24 Episode of tachycardia and ectopic beats, resolved with face cooling and reduction in caffeine dose Mild No
6 37 Death secondary to exacerbation of chronic lung disease (severe bronchopulmonary dysplasia) Severe No
7 26 Death attributed to severe bronchopulmonary dysplasia Severe No
8 57 S aureus bacteraemia and osteomyelitis, resolved with antibiotics Moderate No
9 22 Episode of supraventricular tachycardia, resolved with adenosine Moderate No
10 6 Episode of supraventricular tachycardia, resolved with carotid massage and adenosine Mild No
Each event affected one infant. SUSAR=suspected unexpected serious adverse reactions. 
Table 4: List of serious adverse events reported by randomisation group
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The largest previous trial26 of enteral lactoferrin sup-
plementation, in which 331 very low-birthweight infants 
in a neonatal unit in Italy participated, showed a relative 
risk reduction of 66% (risk ratio 0·34, 95% CI 0·17–0·70) 
for late-onset infection. The participants and the 
intervention were broadly similar to the ELFIN trial, as 
were enteral-feeding practices, including receipt of human 
breast milk versus formula. However, key differences 
in the epidemiology of late-onset infection, as well as in 
infection-prevention practices and exposure to other 
interventions, might have contributed to the difference in 
effects size estimates shown in the two trials. Notably, the 
prevalence of invasive fungal infection was very high in 
the Italian trial (7·7% of the control group) and a 
substantial proportion of the overall effect on reducing 
late-onset invasive infection was due to the effect on 
preventing invasive fungal infection. By contrast, the 
overall prevalence of late-onset fungal infection was low in 
the ELFIN trial (five episodes in total), consistent with that 
reported in UK surveillance studies.2
A limitation of our study was that pre-specified 
primary outcome included both clinically suspected and 
microbiologically confirmed late-onset infection. We 
took this pragmatic approach because of concerns about 
the diagnostic accuracy of microbiological culture of 
blood in this population.25 Standard micro biological 
culture might not detect cases of bacteraemia or 
fungaemia if an insufficient volume of the infant’s blood 
is incubated (ie, false-negative result). Conversely, 
microbiological cultures can also generate false-positive 
results if blood sampling techniques allow entry of 
contaminating microorganisms (typically from the 
infant’s skin). To mitigate these potential sources of bias, 
we used an established consensus case definition that 
required additional evidence of infection (clinical signs 
or biomarkers) and mandated that clinicians indicate an 
intention to treat the infant with antibiotics or 
antifungals for at least 5 days.2
Given that a postulated mechanism of action of 
lactoferrin is to reduce bowel translocation of enteric 
pathogens, we assessed post-hoc whether invasive 
infections with particular groups of enteric organisms 
were reduced. We did not find any evidence that lacto-
ferrin supplementation affected the risk of late-onset 
infection with different groups of infecting micro-
organism including Gram-negative bacteria (mainly 
Escherichia coli and other enterobacteriaceae).
In a post-hoc subgroup analysis of infants who had or 
had not received routine probiotic supplementation 
during the trial period, we did not show any difference in 
the effect of lactoferrin on the risk of late-onset infection. 
A previous trial26 and the 2017 Cochrane review15 have 
suggested that combining supplementation of lactoferrin 
with the probiotic microorganism Lactobacillus rhamnosus 
GG was associated with a greater reduction in the risk of 
late-onset infection and necrotising enterocolitis than 
was lactoferrin supplementation alone. This raises the 
For the Lactoferrin Infant 
Feeding Trial see www.anzctr.
org.au/ACTRN12611000247976.
aspx
possibility that the immunoprotective and prebiotic 
properties of lactoferrin might act synergistically with 
probiotic supplementation.27 Although the ELFIN trial 
did not show any evidence of differential effects 
depending upon whether infants had received probiotics 
during the trial period, the data are not sufficient to 
exclude the possibility that such prebiotic–probiotic 
synergism exists. A 2017 large cluster RCT28 in India has 
suggested that prophylactic administration of an oral 
synbiotic (prebiotic fructo-oligosaccharide combined 
with probiotic Lactobacillus plantarum) reduces infection 
and mortality in late-preterm or term newborn infants. 
We are doing a mechanistic study27 in a subgroup of 
ELFIN trial participants to analyse whether and how 
lactoferrin supplementation affects the intestinal micro-
biome and metabolite profile. The study, which is 
ongoing, will explore changes in microbiomic and 
metabo lomic patterns preceding disease onset, including 
necrotising enterocolitis and late-onset infection. 
Estimates for the secondary outcomes indicated 
consistently that lactoferrin supplementation does not 
have important effects on the risk of major morbidities. 
We prespecified an analysis of the effect on a composite 
of infection, necrotising enterocolitis, bronchopulmonary 
dysplasia, retinopathy of prematurity, or death. The 
adjusted risk ratio point estimate was 1·01 (95% CI 
0·94–1·08), which is consistent with a possible risk 
reduction of up to 6% and a possible increase in risk of up 
to 8%. We plan to increase the precision of the estimates 
of effect on rare secondary outcomes by combining 
these data in a meta-analysis with other trials, including 
a recently completed Australasian RCT of bovine-
lactoferrin supplementation for very low-birth weight 
infants (Lactoferrin Infant Feeding Trial; unpublished).
Since late-onset infection and necrotising enterocolitis 
are the major reasons for receipt of invasive interventions 
and high levels of care in very preterm infants, it is not 
surprising that we did not find any effects on the degree 
of exposure to antimicrobial drugs, on the duration 
of hospitalisation, or on stay in intensive or high-
dependency care settings. Given that the ELFIN trial did 
not show any differences between groups in the risk of 
morbidity or on levels of care received, we did not 
undertake further analyses of health-care costs as had 
been proposed in our approved funding application 
and trial protocol. We did not do a within-trial health 
economic analysis or use these data in a model to explore 
long-term family and health-service costs since these 
are mainly driven by the consequences of infection and 
other morbidity during the initial hospitalisation. With-
out evidence of clinical effectiveness on these infant-
important outcomes, we considered a cost-effectiveness 
analysis of lactoferrin supplementation to be futile.29
We do not plan to apply for permission and funding 
to assess longer-term outcomes of trial participants. We 
specified in our protocol that if the trial did not detect 
significant or clinically important differences in the 
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in-hospital outcomes, then follow-up would not be 
done since any between-group differences in growth 
and neurodevelopmental outcomes are predicated 
largely on differences in the prevalence of late-onset 
infections, necrotising enterocolitis, and associated 
morbidities.4 Since these were not shown, there is no 
longer an impelling rationale for expecting lactoferrin 
supplementation to have an effect on long-term growth 
or development.
The ELFIN trial findings are likely to be applicable in 
the UK and internationally. The trial population was 
representative of very preterm infants cared for within 
health-care facilities in well resourced health services and 
included a substantial proportion of extremely preterm 
infants and of infants with other putative risk factors for 
neonatal morbidity. Overall, about 30% of participants 
acquired a microbiologically confirmed or clinically 
suspected late-onset infection, and about 17% in total had 
a microbiologically confirmed infection, consistent with 
prevalence values reported from cohort studies and other 
RCTs. Similarly, the prevalence of necrotising enterocolitis 
(about 5%) was similar to that reported in large, 
population-based surveillance and cohort studies and 
RCTs.30
In conclusion, the ELFIN trial does not support the 
routine use of enteral bovine lactoferrin supplementation 
to prevent late-onset infection or other morbidity or 
mortality in very preterm infants. Research efforts should 
continue to investigate the aetiology, epidemiology, 
and pathogenesis of late-onset infection and related 
morbidities, and to develop, refine, and assess other 
interventions that could prevent or reduce adverse acute 
and long-term consequences for very preterm infants 
and their families.
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